The PI3Kdelta-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo [CLINICAL AND HUMAN IMMUNOLOGY] - Palazzo, A., Herter, S., Grosmaire, L., Jones, R., Frey, C. R., Limani, F., Bacac, M., Umana, P., Oldham, R. J., Marshall, M. J. E., Cox, K. L., Turaj, A. H., Cragg, M. S., Klein, C., Carter, M. J., Tannheimer, S. (The American Association of Immunologists (AAI), 2018)
6211636
Keywords: WW-YZ